This is encouraging as obviously tutes see this as a long term play. I am hoping for an Acadia like run. $2.50 to $45 in just 2 years without a pipeline and one p3 candidate.
Takeda sticking with OREX plain and simple. Oh well. I sure was hoping for the OREX collapse. Jack really did pick the wrong oriental partner. Little ol' Eisai vs. a gorilla like Takeda.
Great move Jack! Your wisdom is bested only by your greed and incompetence.
Market at all time highs with Nasdaq over 5000 and NYSE over 18000 and is able to buffer the pending Greek mess easily. Over the past 2 years, Arena at nearly multi year lows and likely unable to buffer the oncoming market collapse. Really sucks.
Just when Arena was about to turn the corner and add to what seemed to be incredible news, Jack sells 40% of holdings and follows that with immediate dilution which was the icing on the cake. Thanks Jack. I really mean it.
May I borrow your rose colored glasses? And yes every dark cloud has a silver lining. Rainbows do follow the worst of rainstorms as well.
Saxenda at over $1000 a month with the same efficacy as Belviq worse side effect profile and its injectable already at about 1000 scripts.
That goes to show you the quality of reps or lack thereof makes a huge difference. Eisai reps started off incompetent and now have disappeared completely from the map! It has been months since they have visited my doctor whereas contrave and saxenda reps visiting once or twice a month.
Eisai really dropped the ball from the beginning and Jack should be mad as hell about it. Jack is not. Jack is happy with his salary and free options.
Saxenda at over $1000 a month already cracked 1000 scripts. This is simy because of the higher quality reps. Saxenda and Belviq have the same efficacy. Eisai reps stink of incompetence.
It was $6.30 in January after the big pump and huge dump of Jack Lief shares immediately followed by dilution. No consolation. None.
If it were not for the vivid imagination of several worthy posters, Arena msg board would be deader than Arena stock itself.
$75 without insurance. Medicare patients NOT eligible for discount even if they pay cash. Eisai has got to change this situtation.
I'm still waiting on the infamous Q4 2014 update that would have made 2015 a transformative year for Arena. Jack is a bag full of hot air. In the meantime Jack is cuing up his next batch of stock sales.
These are the kind of studies that reps should be bringing to the attention of doctors but nope. Eisai reps are as dead as door nails. Old study but good study.
An Arena run to $45 will have your Ferrari surrounded by 21 year old hotties. I'm not holding my breath either, especially with Jack and Eisai in command.
Yeah Arena gets hosed tomorrow bad. Oh well. Jack remains quiet. Eisai remains ineffective. Most stocks have had 100-1000% gains since the run began in 2009-2010. Arena remains stuck in the mud at a paltry $4 with no buffer for a market downturn unlike other stocks.
It is clear that Mr. Market could care less about FDA approved drugs. Look at the market cap for ACAD and RCPT just to name a few. Mind boggling.